title: [Value of 5-HT3 receptor antagonists, particularly as anti-emetic drugs].
abstract: Several binding sites for serotonin or 5-hydroxytryptamine (5-HT) were identified by using selective agonists and antagonists. Today, 5-HT3 receptor types are considered to occupy a critical position in the emetic pathway. The discovery of 5-HT3 receptor antagonists originated from metoclopramide, an antidopaminergic drug introduced in France 25 years before as a modifier of digestive motricity; it represents a therapeutic advance, since it led to the first class of antiemetic drugs specifically designed to prevent severe cytotoxic drugs-evoked emesis and devoid of noticeable side-effects. It must be emphasized upon the necessity of developing new experimental tests in living animals and performing controlled trials on patients under chemotherapy to achieve this progress.
authors.forename: P
authors.initials: P
authors.lastname: Lechat
mesh_terms: D000932:Antiemetics / Q000494:pharmacology*; D006801:Humans; D011985:Receptors, Serotonin / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology*; D014839:Vomiting / Q000139:chemically induced / Q000503:physiopathology
chemical_list: D000932:Antiemetics; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists
vernacular_title: Intérêt des antagonistes des récepteurs du type 5-HT3, notamment comme anti-émétiques.